News & insights

Northern Gritstone invests in Manchester spinout Apini

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

• Clinical companies
• Quell Therapeutics

Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer

Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting

• Late-stage clinical companies
• Spur Therapeutics

iOnctura bolsters leadership team with new appointments

• Clinical companies
• iOnctura

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease

• Late-stage clinical companies
• Spur Therapeutics